Logo

AstraZeneca's AZD7442 Fails to Meet its Primary Endpoint in P-III STORM CHASER Study for the Prevention of Symptomatic COVID-19

Share this

AstraZeneca's AZD7442 Fails to Meet its Primary Endpoint in P-III STORM CHASER Study for the Prevention of Symptomatic COVID-19

Shots:

  • The P-III STORM CHASER study involves assessing AZD7442 (300mg) vs PBO for the post-exposure prevention of COVID-19 in 1-121 participants in 59 sites across the UK and US
  • The study did not meet its 1EPs and showed 33% reduction in risk of developing symptomatic COVID-19
  • In a pre-planned analysis of PCR positive & negative participants- AZD7442 showed 73% reduction in the risk of developing symptomatic COVID-19 in participants who were PCR negative at time of dosing. In a post-hoc analysis- in participants who were PCR negative at baseline- AZD7442 reduced the risk of developing symptomatic COVID-19 by 92% more than 7days following dosing- and by 51% up to 7 days following dosing

Ref: AstraZeneca | Image: New Europe

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions